Board of directors
Chairman of the Board since 2016, born 1960. Number of shares: 44 976 Number of warrants 2017/2020: 85 000
Magnus Persson is MD and associate professor in physiology at Karolinska Institutet in Stockholm. Persson has a large amount of experience in the fields of medicine, life sciences and biotech-financing. Persson has previously led development teams in clinical phase II and phase III programmes in the pharmaceutical industry and has founded and led private as well as public biotech and medtech companies, either as chairman or member of the board, in Europe and the USA. Persson has also been involved in multiple IPOs.
Lars H. Bruzelius
Board member since 2013, born 1943. Number of shares: 1 232 682
Lars H. Bruzelius is an associate professor in Business Administration and management consultant with many years of experience working with banks and companies in the energy, medtech and telecommunication industries. Bruzelius is a senior partner in and joint owner of BSI & Partners, and has been a board member and chairman of LU Bioscience AB since 2012. For three years, Bruzelius was the Deputy Chief Executive and Administrative Director of Gambro AB. Bruzelius has been a board member of two listed companies as well as an investor and board member of a number of start-up companies.
Board member since 2016, born 1972. Number of shares: 0
Karin Leandersson is Professor in tumour immunology at the medical faculty of Lund University. She has gained a wide range of cancer research experience in the fields of tumour immunology and tumour inflammation in solid tumours, mainly in breast cancer. Leandersson has also authored around 30 scientific publications in international journals.
Board member since 2010, born 1962. Number of shares: 732 600
Thoas Fioretos is a professor and physician at the Department of Clinical Genetics at Lund University. The focus of his research is molecular and functional studies of genetic changes in leukaemia and how such changes can be used for diagnostic and therapeutic purposes. Fioretos has authored more than 110 scientific publications, and is one of the founders of Cantargia AB and bio-IT company Qlucore AB.
Claus Asbjørn Andersson
Board member since 2013, born 1968. Number of shares: 0
Claus Asbjørn Andersson is a partner of Sunstone Life Science Ventures, a holding company managing billion-dollar venture funds. He has a Master’s degree in Civil Chemical Engineering from Technical University of Denmark and a PhD in Mathematical Statistics from Copenhagen University and Humboldt University of Berlin. Andersson has himself founded four European start-up companies, including two in Denmark. He has been with Sunstone Life Sciences since its establishment in 2007, and is an active member of the International Venture Club and advisor to the European Commission.
Board member since 2016, born 1965. Number of shares: 0
Niclas Lundqvist is a Master of Law specialized in legal counselling with companies listed on the Swedish stock market or MTF. Lundqvist has operational experience from boards of companies listed on the Swedish stock market and companies under the supervision of Finansinspektionen. His previous experience includes other types of legal work, project management and business development in Corporate Finance at Sedermera Fondkommission from 2003 to 2013. Lundqvist is one of the founders of venture capital fund 'Swedish Growth Fund'.
Board member since 2017, born 1963. Number of shares: 0
Patricia Delaite is MD and MBA from University of Geneva and Lausanne. She is currently the Chief Medical Officer for AMAL Therapeutics in Geneva, and has had leading positions at Incytes International Biosciences, ARIAD Pharmaceuticals, Novartis and Eli Lilly. Patricia has also 10 years previous experience in patient clinical managment from the University hospital in Geneva.